MCOW - ETF AI Analysis
Top Page
Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year, showing that its strategy has been working in the current market.
High-Quality Growth Holdings
Several top positions, such as Lattice Semiconductor, Sterling Infrastructure, and Jazz Pharmaceuticals, have shown strong performance, helping drive the fund’s returns.
Sector Diversification Within the U.S.
The fund spreads its investments across technology, industrials, health care, and other sectors, which helps reduce the impact if one industry struggles.
Negative Factors
Moderate Expense Ratio
The fund’s fees are higher than many broad market ETFs, which can slightly reduce long-term returns for investors.
Underperforming Top Holdings
Some large positions like DocuSign, Medpace Holdings, and Manhattan Associates have recently shown weak performance, which can weigh on the ETF’s overall results.
Heavy U.S. and Tech Exposure
With almost all assets in U.S. stocks and a large tilt toward technology, the fund is sensitive to downturns in the U.S. market and the tech sector.
MCOW vs. SPDR S&P 500 ETF (SPY)
AUM1.08M
RegionNorth America
Expense Ratio0.49%
Beta0.96
IssuerPacer
Inception DateAug 27, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedS&P MidCap 400 Quality FCF Aristocrats Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume143
30 Day Avg. Volume1,710
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
26.47Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering77
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MCOW Summary
The Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW) tracks the S&P MidCap 400 Quality FCF Aristocrats Index, focusing on mid-sized U.S. companies with strong and steady cash flow. It holds a mix of technology, industrial, and health care stocks, including well-known names like Lattice Semiconductor and DocuSign. Investors might consider MCOW for growth potential and diversification, since mid-cap companies can offer a balance between smaller, fast-growing firms and larger, more established ones. A key risk is that it is heavily tilted toward technology and mid-cap stocks, so its price can rise and fall more than the overall market.
How much will it cost me?The Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW) has an expense ratio of 0.49%, meaning you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs, as it focuses on a niche strategy targeting mid-cap companies with strong free cash flow, which requires more specialized tracking.
What would affect this ETF?The MCOW ETF, with its focus on mid-cap companies in the U.S., could benefit from continued innovation and growth in the technology and industrial sectors, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as this could increase borrowing costs for mid-sized companies or if economic conditions weaken, impacting consumer spending and business investments. Regulatory changes or sector-specific disruptions in technology or healthcare could also influence the ETF's performance.
MCOW Top 10 Holdings
MCOW is leaning hard into U.S. mid-cap tech and health care, with names like Qualys and Manhattan Associates doing much of the heavy lifting as their shares keep climbing. Lattice Semiconductor and Sterling Infrastructure have been stars over the longer run but are now catching their breath, creating some short-term drag. DocuSign looks more mixed, with recent gains not fully offsetting earlier weakness. Medpace and Jazz Pharmaceuticals add a steady health care backbone. Overall, this is a U.S.-only, quality-focused fund with a clear tilt toward tech-driven cash generators.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Everpure | 6.12% | $66.45K | $33.16B | 25.17% | 64 Neutral | |
| DocuSign | 4.24% | $46.05K | $12.79B | -18.45% | 71 Outperform | |
| Manhattan Associates | 4.16% | $45.14K | $12.46B | -2.53% | 75 Outperform | |
| Medpace Holdings | 3.61% | $39.16K | $16.50B | 21.77% | 79 Outperform | |
| Lattice Semiconductor | 3.24% | $35.23K | $16.46B | 73.84% | 71 Outperform | |
| Exelixis | 2.91% | $31.63K | $14.62B | 56.57% | 78 Outperform | |
| Jazz Pharmaceuticals | 2.42% | $26.24K | $16.02B | 90.07% | 64 Neutral | |
| Qualys | 2.39% | $25.98K | $5.94B | 27.00% | 78 Outperform | |
| Neurocrine | 2.39% | $25.97K | $15.82B | 8.23% | 80 Outperform | |
| Okta | 2.37% | $25.73K | $29.82B | 78.58% | 75 Outperform |
MCOW Technical Analysis
Neutral
―
Price Trends
21.62
Negative
21.06
Positive
20.26
Positive
Market Momentum
-0.06
Positive
41.14
Neutral
25.07
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MCOW, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 21.96, equal to the 50-day MA of 21.62, and equal to the 200-day MA of 20.26, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 41.14 is Neutral, neither overbought nor oversold. The STOCH value of 25.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MCOW.
MCOW Peer Comparison
Comparison Results
Performance Comparison
MCOW
Pacer S&P MidCap 400 Quality FCF Aristocrats ETF
21.35
1.17
5.80%
PAMC
Pacer Lunt MidCap Multi-Factor Alternator ETF
―
―
―
KMID
Virtus KAR Mid-Cap ETF
―
―
―
MMID
MFS Active Mid Cap ETF
―
―
―
SMCP
SMART Mid Cap ETF
―
―
―
MCDS
JPMorgan Fundamental Data Science Mid Core ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents